Authors : Tarkiainen M; New Children's Hospital, Helsinki University Central Hospital, PO Box 705 00029 HUS, Helsinki, Finland. .; Pediatric Research Center, University of Helsinki, Helsinki, Finland. .

Subjects: Arthritis, Juvenile*/Arthritis, Juvenile*/Arthritis, Juvenile*/drug therapy ; Biosimilar Pharmaceuticals*/Biosimilar Pharmaceuticals*/Biosimilar Pharmaceuticals*/therapeutic use ; Antirheumatic Agents*

Source: Pediatric rheumatology online journal [Pediatr Rheumatol Online J] 2022 Nov 16; Vol. 20 (1), pp. 97. Date of Electronic Publication: 2022 Nov 16.Publisher: BioMed Central Country of Publication: England NLM ID: 101248897 Publication Model: Electronic Cited Medium: Internet ISSN: 1546-0096

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

Academic Journal

Potential application of measuring serum infliximab levels in rheumatoid arthritis management: A retrospective study based on KURAMA cohort data.

Authors : Nakae K; Department of Clinical Pharmacology and Therapeutics, Kyoto University Hospital, Kyoto, Japan.; Graduate School of Pharmaceutical Sciences, Kyoto University, Kyoto, Japan.

Subjects: Antirheumatic Agents/Antirheumatic Agents/Antirheumatic Agents/*administration & dosage ; Arthritis, Rheumatoid/Arthritis, Rheumatoid/Arthritis, Rheumatoid/*drug therapy ; Infliximab/Infliximab/Infliximab/*administration & dosage

Source: PloS one [PLoS One] 2021 Oct 13; Vol. 16 (10), pp. e0258601. Date of Electronic Publication: 2021 Oct 13 (Print Publication: 2021).Publisher: Public Library of Science Country of Publication: United States NLM ID: 101285081 Publication Model: eCollection Cited Medium: Internet

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

Academic Journal

Pretreatment resistin levels are associated with erosive disease in early rheumatoid arthritis treated with disease-modifying anti-rheumatic drugs and infliximab.

Authors : Vuolteenaho K; Tuure L ...

Subjects: Antirheumatic Agents*/Antirheumatic Agents*/Antirheumatic Agents*/therapeutic use ; Arthritis, Rheumatoid*/Arthritis, Rheumatoid*/Arthritis, Rheumatoid*/diagnostic imaging ; Arthritis, Rheumatoid*/Arthritis, Rheumatoid*/Arthritis, Rheumatoid*/drug therapy

Source: Scandinavian journal of rheumatology [Scand J Rheumatol] 2022 May; Vol. 51 (3), pp. 180-185. Date of Electronic Publication: 2021 Jul 15.Publisher: Informa Healthcare Country of Publication: England NLM ID: 0321213 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

Academic Journal

Switching to an Infliximab Biosimilar Was Safe and Effective in Dutch Sarcoidosis Patients.

Authors : Peters BJM; Department of Clinical Pharmacy, St. Antonius Hospital, 3430 EM Nieuwegein, The Netherlands.; Bhatoe A

Subjects: Antirheumatic Agents/Antirheumatic Agents/Antirheumatic Agents/*therapeutic use ; Infliximab/Infliximab/Infliximab/*therapeutic use ; Sarcoidosis/Sarcoidosis/Sarcoidosis/*drug therapy

Source: Cells [Cells] 2021 Feb 19; Vol. 10 (2). Date of Electronic Publication: 2021 Feb 19.Publisher: MDPI Country of Publication: Switzerland NLM ID: 101600052 Publication Model: Electronic Cited Medium: Internet ISSN: 2073-4409

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

Academic Journal

A comparative study of PF-06438179/GP1111 (an infliximab biosimilar) and reference infliximab in patients with moderate to severe active rheumatoid arthritis: A subgroup analysis.

Authors : Kameda H; Division of Rheumatology, Department of Internal Medicine, Toho University, Tokyo, Japan.; Uechi E

Subjects: Antirheumatic Agents/Antirheumatic Agents/Antirheumatic Agents/*therapeutic use ; Arthritis, Rheumatoid/Arthritis, Rheumatoid/Arthritis, Rheumatoid/*drug therapy ; Biosimilar Pharmaceuticals/Biosimilar Pharmaceuticals/Biosimilar Pharmaceuticals/*therapeutic use

Source: International journal of rheumatic diseases [Int J Rheum Dis] 2020 Jul; Vol. 23 (7), pp. 876-881. Date of Electronic Publication: 2020 May 31.Publisher: Wiley on behalf of the Asia Pacific League of Associations for Rheumatology Country of Publication: England NLM ID: 101474930 Publication Model:

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

Academic Journal

Pharmacokinetic Similarity of ABP 710, a Proposed Biosimilar to Infliximab: Results From a Randomized, Single-Blind, Single-Dose, Parallel-Group Study in Healthy Subjects.

Authors : Chow V; Clinical Pharmacology, Amgen Inc., Thousand Oaks, California, USA.; Oh M

Subjects: Antibodies, Monoclonal/Antibodies, Monoclonal/Antibodies, Monoclonal/*pharmacokinetics ; Antirheumatic Agents/Antirheumatic Agents/Antirheumatic Agents/*pharmacokinetics ; Infliximab/Infliximab/Infliximab/*pharmacokinetics

Source: Clinical pharmacology in drug development [Clin Pharmacol Drug Dev] 2020 Feb; Vol. 9 (2), pp. 246-255. Date of Electronic Publication: 2019 Oct 19.Publisher: Wiley Country of Publication: United States NLM ID: 101572899 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

Academic Journal

Therapeutic drug monitoring of infliximab compared to standard clinical treatment with infliximab: study protocol for a randomised, controlled, open, parallel-group, phase IV study (the NOR-DRUM study).

Authors : Syversen SW; Department of Rheumatology, Diakonhjemmet Hospital, Box 23 Vinderen, 0319, Oslo, Norway. .; Goll GL

Subjects: Drug Monitoring*; Antirheumatic Agents/Antirheumatic Agents/Antirheumatic Agents/*therapeutic use ; Infliximab/Infliximab/Infliximab/*therapeutic use

Source: Trials [Trials] 2020 Jan 06; Vol. 21 (1), pp. 13. Date of Electronic Publication: 2020 Jan 06.Publisher: BioMed Central Country of Publication: England NLM ID: 101263253 Publication Model: Electronic Cited Medium: Internet ISSN: 1745-6215

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

Academic Journal

A 10-year follow-up of infliximab monotherapy for refractory uveitis in Behçet's syndrome.

Authors : Horiguchi N; Department of Ophthalmology & Visual Science, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University (TMDU), 1-5-45 Yushima, Bunkyo-ku, Tokyo, 113-8519, Japan.; Department of Ophthalmology, Nagano Prefectural Federation of Agricultural Cooperatives for Health and Welfare, Saku General Hospital, Nagano, Japan.

Subjects: Antirheumatic Agents/Antirheumatic Agents/Antirheumatic Agents/*therapeutic use ; Behcet Syndrome/Behcet Syndrome/Behcet Syndrome/*drug therapy ; Infliximab/Infliximab/Infliximab/*therapeutic use

Source: Scientific reports [Sci Rep] 2020 Dec 17; Vol. 10 (1), pp. 22227. Date of Electronic Publication: 2020 Dec 17.Publisher: Nature Publishing Group Country of Publication: England NLM ID: 101563288 Publication Model: Electronic Cited Medium: Internet ISSN:

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

Academic Journal

Presence of anti-nuclear antibodies is a risk factor for the appearance of anti-drug antibodies during infliximab or adalimumab therapy in patients with rheumatoid arthritis.

Authors : Mori A; The Shinko Institute for Medical Research, Shinko Hospital, Kobe, Japan.; Saito T

Subjects: Adalimumab/Adalimumab/Adalimumab/*immunology ; Antibodies/Antibodies/Antibodies/*immunology ; Antirheumatic Agents/Antirheumatic Agents/Antirheumatic Agents/*immunology

Source: PloS one [PLoS One] 2020 Dec 14; Vol. 15 (12), pp. e0243729. Date of Electronic Publication: 2020 Dec 14 (Print Publication: 2020).Publisher: Public Library of Science Country of Publication: United States NLM ID: 101285081 Publication Model: eCollection Cited Medium: Internet

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

Academic Journal

Extracellular Vesicle Biomarkers Reveal Inhibition of Neuroinflammation by Infliximab in Association with Antidepressant Response in Adults with Bipolar Depression.

Authors : Mansur RB; Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, ON M5T 2S8, Canada.; Department of Psychiatry, University of Toronto, Toronto, ON M5T 2S8, Canada.

Subjects: Antidepressive Agents/Antidepressive Agents/Antidepressive Agents/*therapeutic use ; Antirheumatic Agents/Antirheumatic Agents/Antirheumatic Agents/*therapeutic use ; Biomarkers/Biomarkers/Biomarkers/*blood

Source: Cells [Cells] 2020 Apr 06; Vol. 9 (4). Date of Electronic Publication: 2020 Apr 06.Publisher: MDPI Country of Publication: Switzerland NLM ID: 101600052 Publication Model: Electronic Cited Medium: Internet ISSN: 2073-4409

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

نتائج البحث

فلترة النتائج

Economic evaluation of infliximab, synthetic triple therapy and methotrexate in the treatment of newly diagnosed juvenile idiopathic arthritis.

Potential application of measuring serum infliximab levels in rheumatoid arthritis management: A retrospective study based on KURAMA cohort data.

Pretreatment resistin levels are associated with erosive disease in early rheumatoid arthritis treated with disease-modifying anti-rheumatic drugs and infliximab.

Switching to an Infliximab Biosimilar Was Safe and Effective in Dutch Sarcoidosis Patients.

A comparative study of PF-06438179/GP1111 (an infliximab biosimilar) and reference infliximab in patients with moderate to severe active rheumatoid arthritis: A subgroup analysis.

Pharmacokinetic Similarity of ABP 710, a Proposed Biosimilar to Infliximab: Results From a Randomized, Single-Blind, Single-Dose, Parallel-Group Study in Healthy Subjects.

Therapeutic drug monitoring of infliximab compared to standard clinical treatment with infliximab: study protocol for a randomised, controlled, open, parallel-group, phase IV study (the NOR-DRUM study).

A 10-year follow-up of infliximab monotherapy for refractory uveitis in Behçet's syndrome.

Presence of anti-nuclear antibodies is a risk factor for the appearance of anti-drug antibodies during infliximab or adalimumab therapy in patients with rheumatoid arthritis.

Extracellular Vesicle Biomarkers Reveal Inhibition of Neuroinflammation by Infliximab in Association with Antidepressant Response in Adults with Bipolar Depression.

اتصل بنا

اتبع